Filings · News reference
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
Karyopharm Therapeutics has been notified by Nasdaq that its securities will be delisted following the company's Chapter 11 bankruptcy filing.
Karyopharm Therapeutics announced that abstracts for clinical trials evaluating selinexor in myelofibrosis and multiple myeloma have been selected for presentation at the 2026 American Society of Hematology (ASH) annual meeting.
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
Filed: 2026-11-03 AccNo: 0001193125-26-444164 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 1.03: Bankruptcy or Receivership Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Karyopharm Therapeutics Inc. has filed for Chapter 11 bankruptcy protection and entered into a restructuring support agreement to merge with Ayrmid Ltd.